BioEclosion aims to become an international leader in developing the future rapid tests to solve real global social challenges. The core activity of the company relies on the development of new products for the MagnetPlex platform which can range from human diagnostic tests, animal tests, food safety and environmental controls, for instance. MagnetPlex improves the current state-of-art by easing the test performance with a quick, easy to read, one-time use and reliable cartridge embracing the ASSURED guidelines for point-of-need devices. MagnetPlex is composed by two main components: 1) Cartridge: including i) the sample holder containing the magnetic-particles attached to the desired molecular detector (i.e. peptide or antibody) which detects the corresponding biomarker present in whole blood, serum or plasma samples, and ii) the magnetic vertical-flow biosensor wherein the electrochemical quantitative readout is performed, while the excess of sample and reagents are removed by cap...
BioEclosion aims to become an international leader in developing the future rapid tests to solve real global social challenges. The core activity of the company relies on the development of new products for the MagnetPlex platform which can range from human diagnostic tests, animal tests, food safety and environmental controls, for instance. MagnetPlex improves the current state-of-art by easing the test performance with a quick, easy to read, one-time use and reliable cartridge embracing the ASSURED guidelines for point-of-need devices. MagnetPlex is composed by two main components: 1) Cartridge: including i) the sample holder containing the magnetic-particles attached to the desired molecular detector (i.e. peptide or antibody) which detects the corresponding biomarker present in whole blood, serum or plasma samples, and ii) the magnetic vertical-flow biosensor wherein the electrochemical quantitative readout is performed, while the excess of sample and reagents are removed by capillarity and; 2) Tablet: including the USB cable which connects the cartridge and the Android tablet allowing the quantitative electrochemical readout in less than one minute, of levels of biomarker as units above the cut-off value or upper normal threshold by using an App. MagnetPlex cartridge requires no change to current clinical practice for obtaining patient specimens and no special tools or equipment beyond a standard tablet for readout. Moreover, it can be extended to low resource settings in emerging countries with no developed health systems. Based in MagnetPlex, BioEclosion is developing the first product of the company, CeliFast, an in vitro point-of-need quantitative test for the early detection of celiac disease in only 5 minutes at practitioners’ site and at a much-reduced cost. Currently the company has the exclusive worldwide rights of exploitation of the PCT/ES2015/070097 protecting the magnetic beads coupled to a biomarker able to detect celiac disease. This patent has already been granted in US and EU, and under review in Canada. BioEclosion will also invest in open innovation and develop the product pipeline according to market needs. BioEclosion will outsource all the key activities of the company such as manufacturing and product commercialization which should be flexible and easy to escalate thorough the new potential products, geographically adaptable and even to the data collection business.
More information